The phase 2 KRYSTAL-7 study evaluated the use of adagrasib plus pembrolizumab as first-line therapy for patients with advanced/metastatic KRAS G12C-mutated NSCLC.4 Here, KRAS is linked to non-small cell lung carcinoma.